Tracer library / [212Pb]Pb-AB001
[212Pb]Pb-AB001
Also written as [Pb-212]Pb-AB001
- Radionuclide
- Pb-212 t½ 638.4 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- PSMA-targeting peptide radioligand (NG001/AB001) chelated with p-SCN-Bn-TCMC
- Target / mechanism
- PSMA-targeting alpha-emitting radioligand PMID 40694184
- Clinical application
- Alpha-particle radioligand therapy for metastatic castration-resistant prostate cancer, including micrometastatic disease PMID 40397137
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >95% | AB001 ligand (previously referred to as…AB001 ligand (previously referred to as NG001) MedKoo Biosciences Inc., Morrisville, NC, USA | 40694184 2025 Med Oncol The AB001 ligand (previously referred to as NG001, MedKoo Biosciences Inc., Morrisville, NC, USA) was then added to achieve a specific activity of 2 MBq/µg (3.32 MBq/nmol), following the procedure described by Stenberg et al. [27]. |
| Manual synthesis | — | — | — | — | AB001 ligand MedKoo Biosciences | 40397137 2025 Eur J Nucl Med Mol Imaging Radiolabelling, quality control and radioactive measurements followed established protocols |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.2025 · J Nucl Med · Clinical study · Phase 0
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- MedKoo Biosciences, MedKoo Biosciences Inc., Morrisville, NC
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [212Pb]Pb-AB001, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41710577: 'combines a prostate-specific membrane antigen (PSMA)-targeting peptide (NG001) (Figure 5) with the alpha-emitting radionuclide 212Pb, chelated via the bifunctional chelator para-isothiocyanatobenzyl-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)cyclododecane (p-SCN-Bn-TCMC)'.